CLINICAL TRIALS
Click below to learn more about current Vical clinical trials for specific cancer and infectious disease applications.
INVESTOR INFO
| NASDAQ: VICL | |
WELCOME TO VICAL
Vical researches and develops biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
VAXFECTIN®
Vical's proprietary Vaxfectin® adjuvant has demonstrated safety and effectiveness in a number of animal models. In July 2008, we announced preliminary clinical trial data demonstrating that Vaxfectin®-formulated DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans. References to published data are included in the Vaxfectin® Publications page.